ICI 74,917: a new anti-allergic drug administered by pressurised aerosol.

Ten patients with allergic rhinitis were challenged intranasally with allergen before, and half an hour, 2 hours and 4 hours after intranasal administration of placebo, disodium cromoglycate powder and an aerosol containing ICI 74,917, a new compound with anti-allergic action. ICI 74,917 had a maximum protective effect after half an hour, but was significantly better than placebo 2 hours after nasal use. The effect was significantly better than that of disodium cromoglycate powder. The results will encourage studies of ICI 74,917 in the treatment of allergic rhinitis.

RCT Entities:   Population Interventions Outcomes